Register to receive a free Soft Tissue Repair Market Analysis, Size, and Trends Report synopsis and brochure.
Exogenesis, a developer of proprietary nanoscale surface modification and surface announced a new milestone in hernia repair. Their Exogenesis nanoMesh recently received clearance from the FDA. The soft tissue repair implant is designed to facilitate tissue ingrowth to reinforce hernias or defects, while at the same time reducing the inflammatory response and fibrous encapsulation.
The mesh is designed from polypropylene fibers that are warp-knitted into each other. The device is thin and density and has large pores. The Exogenesis nanoMesh is said to offer favorable post-implant tissue compatibility. These positive results are accredited to Exogenesis’ proprietary accelerated neutral atom beam (ANAB) technology.
One of iData Research’s findings regarding the hernia repair segment of the soft tissue repair market is that there is evidence demonstrating that certain synthetic mesh materials have been related to specific complications following hernia repair. Furthermore, it has also been found that placement of a prosthetic mesh in a contaminated field is associated with a high rate of wound infections and subsequent mesh removal. The Exogenic nanoMesh is reported to positively impact tissue integration as a result of its ANAB technology. This innovation will positively contribute to the hernia repair segment of the market, as it will reduce patient complications post-surgery.
“We are thrilled to receive FDA clearance of the Exogenesis hernia mesh premarket application,” president and CEO Dmitry Shashkov said in prepared remarks. “We are currently completing commercial channel development for this novel product and look forward to bringing it to the clinical community in the near future.”
New England Hernia Center director, Dr. David Earle, stated that the “advances in mesh technology are critical to further improving patient outcomes in hernia repair.” He considers “surface modification at the nanoscale as one of the most important recent technological advances. Exogenesis’ FDA clearance is a crucial step in this direction.”
For Further Information
To get in an in-depth market overview, as well as insight through primary research and procedural volumes from 16 countries, please read iData Research’s’ 1940 page Soft Tissue Repair Market Analysis, Size, and Trends Report.
